세계의 치료제 모니터링(TDM) 시장 : 제품별, 기술별, 약물군별, 치료 분야별, 검체별, 최종사용자별 - 예측(-2029년)

It is anticipated that the therapeutic drug monitoring market will grow from USD 2.30 billion in 2024 to USD 3.44 billion by 2029, with a steady compound annual growth rate (CAGR) of 8.4%. Advancements in immunoassay techniques remain a key driver of this growth, influencing the sector's trajectory in a positive manner. These techniques aim to improve the accuracy, speed, and specificity of medication monitoring, including enhanced chemiluminescence, ELISA, and fluorescence enhancement. In the meantime, healthcare professionals are becoming more aware of the significance of TDM in improving therapeutic outcomes, leading to its incorporation into clinical settings. Education and training initiatives have raised clinicians' understanding of the advantages of TDM, making it easier for the technology to be implemented in everyday patient care. Collaboratively, these elements are influencing a dynamic and growing market environment.

"Consumables segment is expected to grow at the highest CAGR during the forecast period, by product."

The consumables segment holds the highest CAGR in the therapeutic drug monitoring. Consumables such as reagents, assay kits, and calibrators create a very important part in the TDM market as they are integral in routine monitoring of drugs for chronic but complex-to-cure conditions such as cancer, cardiovascular, and neurological disorders. Demand for high-quality consumables is growing as a result of the increased focus on customized therapy and the need for precise medication level evaluation. Additionally, spending money on advanced TDM systems produced by labs and hospitals would raise demand for its related goods, which would support market expansion.

"Blood segment is expected to hold the largest share of TDM market during the forecast period, by specimen."

Blood, as it is the most used specimen for TDM, fuels the market owing to its capability to provide precise and direct measurement of drug concentrations in plasma or serum. Well-established protocols in the collection and processing of blood ensure that it is reliable and consistent, while its wide clinical acceptance is well established. It is compatible with the most advanced technologies, including immunoassays and LC-MS/MS, by which drugs can be accurately quantified, meeting modern demands in therapeutic monitoring. Besides, this is supported by regulatory guidelines and clinical practices, which favor blood-based TDM; it has proved its merit in monitoring pharmacokinetics for the optimization of dose , which improves therapeutic outcomes, all combining to favor its adoption in a clinical setting.

"US to grow at the highest CAGR for North America therapeutic drug monitoring market"

The increasing prevalence in the US of chronic diseases of a cardiovascular nature, diabetes, neurological disorders, and cancer, among many others, significantly fuels this demand for TDM. Several of these disorders require thorough monitoring for the optimization of their treatment efficacy by taking measures to reduce adverse events, hence increasing the pace of adoption of TDM technologies. The well-established and well-developed healthcare framework of the country involves large numbers of hospitals, laboratories, and diagnostic centers, which further fortifies the integration of advanced end. Besides, continuous innovation in TDM technologies, supported by the presence of numerous pharmaceutical and biotech companies, ensures availability and advances in monitoring tools. These are all factors combined to spur the rapid growth of the TDM market in the US.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the therapeutic drug monitoringmarketplace.

• By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
• By Designation: C-level Executives - 30%, Directors - 34%, and Others - 36%
• By Region: North America- 40%, Europe - 25%, Asia Pacific- 19%, Latin America- 8%, Middle East & Africa- 6% and GCC Countries- 2%

The companies included in Therapeutic Drug Monitoring market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK), apDia Group (Belgium), BBI Solutions (UK), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), UTAK (US), Sekisui Medical Co., Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), BUHLMANN Laboratories AG (Switzerland), SJK Global, LLC (US), Epitope Diagnostics, Inc. (US), QED Bioscience Inc. (US), Boditech Med Inc. (South Korea), and Immunodiagnostic Systems (UK).

Research Coverage

This research report categorizes the therapeutic drug monitoring market by product (Equipment, and Consumables), by technology (Immunoassays, Chromatography-MS, and Other Technologies), by Drug Class (Anti-Epileptic Drugs, Anti-Arrhythmic Drugs, Immunosuppressant Drugs, Antibiotic Drugs, Bronchodilator Drugs, Psychoactive Drugs, and Other Drug Classes), by Therapeutic Area (Neurological Disorders , Cardiology, Infectious Diseases, Oncology, Other Therapeutic Areas), by Specimen (Blood, Saliva, and other samples), by End User (Hospital Laboratories, Commercial & Private Laboratories, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Gountries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the therapeutic drug monitoring market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the therapeutic drug monitoring market. Competitive analysis of upcoming startups in the therapeutic drug monitoring market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall therapeutic drug monitoring market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Importance of therapeutic drug monitoring in organ transplant procedures, Use of therapeutic drug monitoring across various therapeutic fields, Increasing preferences for precision medicine, Growing focus on R&D related to therapeutic drug monitoring, Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, Increase in prevalence of Epilepsy, Rising prevalence of cancer to drive adoption of Therapeutic Drug Monitoring in Oncology Treatments), restraints (High capital investments, Reluctance of small hospitals to offer therapeutic drug monitoring services), opportunities (Significant opportunities in BRICS countries, Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring, Integration of AI and machine learning), and challenges (Alternatives to conventional therapeutic drug monitoring, Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries, Shortage of skilled professionals) influencing the growth of the therapeutic drug monitoring market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the therapeutic drug monitoring market
• Market Development: Comprehensive information about lucrative markets - the report analyses the therapeutic drug monitoring market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the therapeutic drug monitoring market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK)) among others in therapeutic drug monitoring market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Lab-based analysis
    • 2.2.1.3 Approach 3: Drug class-based analysis
    • 2.2.1.4 Approach 4: Presentations of companies and primary interviews
    • 2.2.1.5 Growth forecast
    • 2.2.1.6 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ASSESSMENT
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 STUDY LIMITATIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
• 4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SHARE, BY DRUG CLASS AND COUNTRY (2023)
• 4.3 THERAPEUTIC DRUG MONITORING MARKET, BY KEY COUNTRY
• 4.4 THERAPEUTIC DRUG MONITORING MARKET: REGIONAL MIX, 2024-2029
• 4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Importance of therapeutic drug monitoring in organ transplant procedures
    • 5.2.1.2 Use of therapeutic drug monitoring across various therapeutic fields
    • 5.2.1.3 Increasing preference for precision medicine
    • 5.2.1.4 Growing focus on R&D related to therapeutic drug monitoring
    • 5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
    • 5.2.1.6 Increasing prevalence of epilepsy
    • 5.2.1.7 Rising prevalence of cancer
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital investments
    • 5.2.2.2 Reluctance of small hospitals to offer therapeutic drug monitoring services
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Significant opportunities in BRICS countries
    • 5.2.3.2 Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring
    • 5.2.3.3 Integration of AI and machine learning
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Alternatives to conventional therapeutic drug monitoring
    • 5.2.4.2 Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries
    • 5.2.4.3 Shortage of skilled professionals
• 5.3 PRICING ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 REGULATORY LANDSCAPE
  • 5.7.1 NORTH AMERICA
    • 5.7.1.1 US
    • 5.7.1.2 Canada
  • 5.7.2 EUROPE
  • 5.7.3 ASIA PACIFIC
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
  • 5.7.4 LATIN AMERICA
  • 5.7.5 MIDDLE EAST
  • 5.7.6 AFRICA
• 5.8 TRADE ANALYSIS
• 5.9 PATENT ANALYSIS
• 5.10 KEY CONFERENCES AND EVENTS IN 2025 AND 2026
• 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGY
    • 5.12.1.1 Enzyme-linked immunosorbent assay
  • 5.12.2 COMPLEMENTARY TECHNOLOGY
    • 5.12.2.1 Liquid chromatography-mass spectrometry
  • 5.12.3 ADJACENT TECHNOLOGY
    • 5.12.3.1 Electrophoresis
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 THREAT OF SUBSTITUTES
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT AND FUNDING SCENARIO
• 5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC DRUG MONITORING MARKET

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET
• 6.3 EQUIPMENT
  • 6.3.1 IMMUNOASSAY ANALYZERS
    • 6.3.1.1 High efficiency to drive adoption
  • 6.3.2 CHROMATOGRAPHY & MS DETECTORS
    • 6.3.2.1 Technological advancements to propel growth
  • 6.3.3 CLINICAL CHEMISTRY ANALYZERS
    • 6.3.3.1 Increasing incidence of chronic and complex diseases to drive market

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 IMMUNOASSAYS
  • 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
    • 7.2.1.1 Accurate measurement of target-specific proteins to drive market
  • 7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
    • 7.2.2.1 Rapid detection time and good specificity to support growth
  • 7.2.3 FLUORESCENCE IMMUNOASSAYS
    • 7.2.3.1 High operability and better sensitivity of FIAs to drive market
  • 7.2.4 COLORIMETRIC IMMUNOASSAYS
    • 7.2.4.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
  • 7.2.5 OTHER IMMUNOASSAYS
• 7.3 CHROMATOGRAPHY-MS
  • 7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
    • 7.3.1.1 High accuracy to drive demand for LC-MS
  • 7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
    • 7.3.2.1 Drawbacks of GC-MS to challenge market growth
• 7.4 OTHER TECHNOLOGIES

8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS

• 8.1 INTRODUCTION
• 8.2 ANTIEPILEPTIC DRUGS
  • 8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
• 8.3 ANTIARRHYTHMIC DRUGS
  • 8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
• 8.4 IMMUNOSUPPRESSANT DRUGS
  • 8.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES TO DRIVE MARKET
• 8.5 ANTIBIOTIC DRUGS
  • 8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND
• 8.6 BRONCHODILATOR DRUGS
  • 8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
• 8.7 PSYCHOACTIVE DRUGS
  • 8.7.1 RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
• 8.8 OTHER DRUGS

9 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 NEUROLOGICAL DISORDERS
  • 9.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
• 9.3 CARDIOLOGY
  • 9.3.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
• 9.4 INFECTIOUS DISEASES
  • 9.4.1 INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND
• 9.5 ONCOLOGY
  • 9.5.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET
• 9.6 OTHER THERAPEUTIC AREAS

10 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN

• 10.1 INTRODUCTION
• 10.2 BLOOD
  • 10.2.1 INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET
• 10.3 SALIVA
  • 10.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
• 10.4 OTHER SAMPLES

11 THERAPEUTIC DRUG MONITORING MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITAL LABORATORIES
  • 11.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO DRIVE MARKET
• 11.3 COMMERCIAL & PRIVATE LABORATORIES
  • 11.3.1 EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
• 11.4 OTHER END USERS

12 THERAPEUTIC DRUG MONITORING MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 12.2.2 US
    • 12.2.2.1 Increasing awareness regarding precision medicine to propel market
  • 12.2.3 CANADA
    • 12.2.3.1 Availability of funding for research to offer growth opportunities
• 12.3 EUROPE
• 12.4 EUROPE: MACROECONOMIC OUTLOOK
  • 12.4.1 GERMANY
    • 12.4.1.1 Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth
  • 12.4.2 UK
    • 12.4.2.1 Increasing cases of chronic diseases to drive market
  • 12.4.3 FRANCE
    • 12.4.3.1 Rising awareness of benefits of therapeutic drug monitoring to accelerate demand
  • 12.4.4 ITALY
    • 12.4.4.1 Rising incidence of cancer to drive demand
  • 12.4.5 SPAIN
    • 12.4.5.1 Adoption of technologically advanced immunoassays to boost market
  • 12.4.6 REST OF EUROPE
• 12.5 ASIA PACIFIC
• 12.6 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 12.6.1 JAPAN
    • 12.6.1.1 High prevalence of chronic diseases and advanced healthcare infrastructure to drive market
  • 12.6.2 CHINA
    • 12.6.2.1 Rising number of organ transplants to boost market
  • 12.6.3 INDIA
    • 12.6.3.1 Rising incidence of cancer to propel market
  • 12.6.4 AUSTRALIA
    • 12.6.4.1 High healthcare expenditure and favorable government initiatives to propel market
  • 12.6.5 REST OF ASIA PACIFIC
• 12.7 LATIN AMERICA
  • 12.7.1 INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
  • 12.7.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
• 12.8 MIDDLE EAST & AFRICA
  • 12.8.1 INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET
  • 12.8.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
• 12.9 GCC COUNTRIES
  • 12.9.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
  • 12.9.2 GCC COUNTRIES: MACROECONOMIC OUTLOOK

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 RIGHT TO WIN
• 13.3 STRATEGIES ADOPTED BY KEY PLAYERS
• 13.4 REVENUE ANALYSIS
• 13.5 MARKET SHARE ANALYSIS
• 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS
  • 13.6.1 STARS
  • 13.6.2 EMERGING LEADERS
  • 13.6.3 PERVASIVE PLAYERS
  • 13.6.4 PARTICIPANTS
  • 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.6.5.1 Company footprint
    • 13.6.5.2 Region footprint
    • 13.6.5.3 Product footprint
    • 13.6.5.4 Technology footprint
    • 13.6.5.5 End-user footprint
• 13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES
  • 13.7.1 PROGRESSIVE COMPANIES
  • 13.7.2 RESPONSIVE COMPANIES
  • 13.7.3 DYNAMIC COMPANIES
  • 13.7.4 STARTING BLOCKS
  • 13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 13.7.5.1 Detailed list of key startups/SMEs
• 13.8 COMPANY VALUATION & FINANCIAL METRICS
  • 13.8.1 FINANCIAL METRICS
  • 13.8.2 COMPANY VALUATION
• 13.9 PRODUCT/BRAND COMPARISON
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES
  • 13.10.2 DEALS
  • 13.10.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 ABBOTT
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 MnM view
      • 14.1.1.3.1 Key strengths
      • 14.1.1.3.2 Strategic choices
      • 14.1.1.3.3 Weaknesses and competitive threats
  • 14.1.2 THERMO FISHER SCIENTIFIC INC.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
      • 14.1.2.3.2 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 SIEMENS HEALTHINEERS AG
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 DANAHER CORPORATION
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 BIO-RAD LABORATORIES, INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches
      • 14.1.6.3.2 Deals
  • 14.1.7 BIOMERIEUX SA
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
  • 14.1.8 BIOSYNEX SA
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
      • 14.1.8.3.2 Deals
  • 14.1.9 GRIFOLS, S.A.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
  • 14.1.10 EXAGEN INC.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Deals
  • 14.1.11 ARK DIAGNOSTICS, INC.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
  • 14.1.12 R-BIOPHARM AG
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches
  • 14.1.13 RANDOX LABORATORIES LTD.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 APDIA GROUP
  • 14.2.2 BBI SOLUTIONS
  • 14.2.3 EAGLE BIOSCIENCES, INC.
  • 14.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
  • 14.2.5 AALTO SCIENTIFIC, LTD.
  • 14.2.6 IMMUNDIAGNOSTIK AG
  • 14.2.7 UTAK
  • 14.2.8 SEKISUI MEDICAL CO., LTD.
  • 14.2.9 DIASYSTEM SCANDINAVIA AB
  • 14.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
  • 14.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
  • 14.2.12 BUHLMANN LABORATORIES AG
  • 14.2.13 SJK GLOBAL, LLC
  • 14.2.14 EPITOPE DIAGNOSTICS, INC.
  • 14.2.15 QED BIOSCIENCE INC.
  • 14.2.16 BODITECH MED INC.
  • 14.2.17 IMMUNODIAGNOSTIC SYSTEMS

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS